March 9, 2021 -- InvestorsHub NewsWire -- via MarketWatch -- PAO
Group, Inc.'s (USOTC: PAOG)
stock has been trading in sympathy with the broader OTC
markets...lower. But a green session on Friday, followed by a
roughly 37% move higher on Monday, shows that when investors
embrace risk back into their portfolios, PAOG can be a standout
performer.
In fact, while its 2-day performance was strong, those gains
appear to link to recent updates that legitimize the bullishness.
There, PAOG has highlighted plans that are already in motion
designed to accelerate revenue growth in the coming quarters. Of
note, PAOG is already a revenue-generating company and expects that
milestone to continue during the next six quarters.
Better still, as a revenue-generating company, PAOG is not only
performing better than hundreds of nano-cap peers but also may be
doing as well as some CBD-focused mid-caps that are yet to get a
product to market. And while PAOG's $300,000 in revenues from its
cannabis cultivation subsidiary have sent share prices higher, more
exponential gains can come when PAOG proves to shareholders that it
can leverage its revenues to capitalize on emerging opportunities
in the CBD and nutraceuticals markets. Several deals are helping to
make that happen.
Its RespRx acquisition could lead the growth.
Partnerships, Acquisitions, And Patented Assets Set Up 2021
Shareholders sent shares higher in 2020 after PAOG announced its
acquisition of RespRx. That asset enables PAOG to accelerate its
initiatives to develop CBD alternatives to treat patients with
symptoms associated with Chronic Obstructive Pulmonary Disorder
(COPD). But, while investors wanted rapid program development, the
Trump administration slowed things down for the entire sector.
CBD-based therapeutics was simply not high on his political
agenda.
Thus, when markets rotated, and CBD-based therapeutics were less
focused on, the sector's smaller stocks took significant hits to
their valuations. That was terrible news for PAOG. However, the
excellent news now is that PAOG is now better positioned to advance
its strategic initiatives compared to 2020.
Undoubtedly, when PAOG acquired RespRx from Kali-Extracts, it
was viewed as a potentially transformative acquisition. That's
still the case. And while the pace of development has slowed until
now, RespRx remains a tremendous asset that can be commercialized
to target multiple indications where a better and safer standard of
care is needed.
Still, it's important to remember that developing treatments for
multiple indications is costly and timely. Investors in "big
pharma" wait years after a drug trial is announced to get results,
and many times, even after several years of waiting, those drug
trials can't advance out of a phase 2 trial. The same patience
needs to be afforded to PAOG. Investors should also keep in mind
RespRx, and its patented cannabis extraction process could be
money-makers without the need to bring a single product to market.
In fact, comments made by the inventor of the extraction process
said that his method was professionally recognized as producing
better quality CBD extracts than GW Pharma (GWPH), a
leading company that was purchased by Jazz Pharma for $7.2 billion
last February. That quality could lead to licensing, partnerships,
and collaborative agreements.
And GW Pharma, by the way, is an example of a company that spent
years going against the grain, had big pharma gunning for them, and
still proved that CBD-based therapeutics could play a vital role in
treating a variety of patient conditions. In turn, one of the "big
pharma" that may have criticized the science instead embraced it
with a multi-billion dollar purchase.
Better still, PAOG is entering 2021 with multiple shots on goal.
In fact, beyond its COPD pharmaceutical initiatives, PAOG is
advancing a nutraceutical product line that they believe will
compete effectively against already marketed, higher-priced
brands.
Nutraceuticals Can Be A Game-Changer
There, PAOG announced engaging with the Puerto Rico Consortium
for Clinical Investigation (PRCCI) to assist with developing its
proprietary Cannabidiol (CBD) extract into a nutraceutical product.
The agreement adds credibility and sector expertise to the
initiative and can help expedite approval if the two successfully
develop an effective CBD-based treatment to target COPD's
debilitating effects.
The goal is to develop CBD-based treatments to replace addictive
and often harmful prescription drugs. And as CBD-based therapeutics
become more mainstream, the company hopes to receive fast-track
review and approval from regulatory agencies acceptance of CBD and
cannabinoid compounds as viable and effective treatment
options.
Other deals are in place to push its CBD nutraceutical
operations. In a multimedia
presentation, PAOG detailed its CBD nutraceutical development
expansion plans and explained how strategic engagements with
Puration, Inc. (USOTC: PURA),
North American Cannabis Holdings, Inc. (USOTC:
USMJ), and Alkame Holdings, Inc. (USOTC: ALKM)
can accelerate growth in multiple directions.
In fact, the breadth of news is keeping investors interested in
the stock, and despite recent sector-wide weakness, PAOG has been
able to hold its roughly 300% share price increase since the start
of the year.
The trend higher is likely to continue when risk makes its way
back into the markets. At current share prices, the opportunity may
be significant.
Video Link: https://www.youtube.com/embed/p48PfDlIABQ
Partnerships And New Revenues
Perhaps the not-so-hidden gem in all of the discussion is that
PAO Group is doing what most of its peers are not
doing...generating revenues. And that metric puts the company in an
enviable position to capitalize on new opportunities and develop
its existing pipeline.
Also, a deal with Alkame Holdings Inc. (OTC
PINK: ALKM) to develop and distribute its CBD nutraceuticals
adds depth to its commercialization plans and strengthens the
operations' logistical side. In other words, PAOG has a
distribution infrastructure already in place that can streamline
costs and accelerate commercialization later. Another deal with
North American Cannabis Holdings, Inc. (OTC
Pink: USMJ), which
is expected to take on the distributor's role, completes the
distribution circle.
The message that PAOG makes to its investors is to respect the
time needed for development. CBD-based medicine is a new science
despite the numerous headlines, and its popularity and
billion-dollar market opportunities send a clear message- CBD-based
therapeutics are the real deal.
Allow 2021 To Develop
Thus, PAOG has the same opportunities as other development-stage
companies. Moreover, they have a crucial asset in RespRx and are
generating revenue to help push programs forward. Also noteworthy
is that PAOG is making strategic deals with industry companies that
can expedite program development, add to its existing revenues
stream, and position it to leverage its patented CBD extraction
process to capitalize on substantial market
opportunities.
Therefore, given time, PAOG can capitalize on its assets and
transform itself from the development-stage to a
commercialization-stage company. And in 99.99% of situations, that
transformation leads to exponential returns. Sometimes, it just
takes time.
Disclaimers: Hawk Point Media is responsible for the
production and distribution of this content. Hawk Point Media is
not operated by a licensed broker, a dealer, or a registered
investment adviser. It should be expressly understood that under no
circumstances does any information published herein represent a
recommendation to buy or sell a security. Our
reports/releases are a commercial advertisement and are for general
information purposes ONLY. We are engaged in the business of
marketing and advertising companies for monetary compensation.
Never invest in any stock featured on our site or emails unless you
can afford to lose your entire investment. The
information made available by Hawk Point Media is not intended to
be, nor does it constitute, investment advice or recommendations.
The contributors may buy and sell securities before and after any
particular article, report and publication. In no event shall Hawk
Point Media be liable to any member, guest or third party for any
damages of any kind arising out of the use of any content or other
material published or made available by Hawk Point Media,
including, without limitation, any investment losses, lost profits,
lost opportunity, special, incidental, indirect, consequential or
punitive damages. Hawk Point Media was compensated
three-thousand-five-hundred-dollars by wire transfer to produce
research, video, email, newsletters, and editorial commentary for
PAO Holdings Group, Inc.. by a third party. Past performance is a
poor indicator of future performance. The information in this
video, article, and in its related newsletters, is not intended to
be, nor does it constitute, investment advice or recommendations.
Hawk Point Media strongly urges you conduct a
complete and independent investigation of the respective companies
and consideration of all pertinent risks. Readers are advised to
review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider
reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995
provides investors a safe harbor in regard to forward-looking
statements. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, goals, assumptions or future events or performance are
not statements of historical fact may be forward looking
statements. Forward looking statements are based on expectations,
estimates, and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be
identified through use of words such as projects, foresee, expects,
will, anticipates, estimates, believes, understands, or that by
statements indicating certain actions & quote; may, could, or
might occur. Understand there is no guarantee past performance will
be indicative of future results.Investing in
micro-cap and growth securities is highly speculative and carries
an extremely high degree of risk. It is possible that an investors
investment may be lost or impaired due to the speculative nature of
the companies profiled.
Media Contact
Company Name: Hawk Point Media
Contact Person: Jake Ellis
Email: Send
Email
City: Miami Beach
State: Florida
Country: United States
Website: https://www.greenlightstocks.com
Source - MarketWatch https://www.marketwatch.com/press-release/pao-group-incs-shares-rally-investors-embrace-its-innovative-therapeutics-and-its-revenue-generating-partnerships-2021-03-09
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Apr 2023 to Apr 2024